CD7 CAR-T Cells in T-cell Lymphoma/Leukemia

T-cell lymphoma/leukemia is a group of highly lethal diseases with a high relapse rate and poor prognosis. CD7 was proved to be widely expressed in T-cell malignant, which makes it a promising therapeutic target. In this study we aim to test the safety and efficacy of CD7 CAR-T cells in T-cell lymphoma/leukemia.

Trial Details

NCT ID
NCT05620680
Phase
NA
Sponsor
Shenzhen University General Hospital
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • CD7 CAR-T cells
Locations (sample)
  • Shenzhen, Guangdong, China|22.54554,114.0683

Key Eligibility Criteria

  • Age 18-75 (≥ 18 years old, ≤ 75 years old), gender is not limited;
  • The subject voluntarily participates in the research and signs the "Informed Consent" by himself or his legal guardian;
  • According to the National Comprehensive Cancer Network (NCCN) T lymphocytic lymphoma (2020.V1)/acute lymphoblastic leukemia (2020. V1) practice gui…
  • Meet the diagnostic criteria for relapsed/refractory T-cell lymphoma, including any of the following:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →